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Virtually all methicillin-resistant Stu.hyZococcus uureus 
(MRSA) infections in the largest Portuguese teaching 
hospital are caused by two internationally spread 
multiresistant strains: the 'Iberian' and the 'Brazilian' 
clones of MRSA 
D. Oliveiva', I.  Santos-Sanches1)2, R. Mato', M.  tar nay^'>^, G. Ribeiro4, D. Costa4 
and H. de Len~as tve lJ~~ 
'Molecular Genetics Unit, Instituto de Tecnologia Quimica e Biol6gica (ITQB), Universidade Nova 
de Lisboa, Oeiras, Portugal; 2Faculdade de Ciincias e Tecnologia (FCT), Universidade Nova de 
Lisboa, Monte da Caparica, Portugal; 3Ministerio de Salud Instituto Nacional de Salud, Laboratorio 
de Microbiologia, Santa Fir de Bogoti, Colombia; 4Hospitais da Universidade de Coimbra, Coimbra, 
Portugal; 5Laboratory of Microbiology, The Rockefeller University, New York, USA 
Objective: TO determine the nature (clonal type and antibiotic resistance pattern) of methicillin-resistant Staphylococcus 
aureus (MRSA) strains recovered from the largest teaching hospital in Portugal and to detect temporal trends in clonal 
types during three consecutive surveillance periods in 1992-93,1994-95 and 1996. 
Methods: MRSA strains were characterized by chromosomal Smal macrorestriction patterns using pulsed-field gel 
electrophoresis (PFGE) and by DNA fingerprints-applied to Clal digests-apable of probing two specific areas of the 
staphylococcal chromosome: (1) the vicinity of the mecA gene, and (2) the attachment site(s) and copy number of 
transposon Tn554. The combination of these methods can generate 'clonal types' useful for epidemiological tracking of 
MRSA strains. 
Results: During the 1992-93 collection period, 65% of MRSA strains carried the mecA polymorph I, Tn554 pattern E and 
PFGE pattern A (1::E::A)-a clonal type that was used to define the 'Iberian MRSA', which is widely spread throughout 
southern Europe. The representation of this clone decreased to 42% in 1994-95 and to 20% in 1996. At the same time, 
a second multiresistant MRSA strain carrying mecA polymorph XI, Tn554 type B and PFGE pattern B (XI::B::B)-a clonal 
type characteristic of the so-called 'Brazilian MRSA'-increased from 5% in 1992-93 to 36% in 1994-95 and 29% in 1996. 
Conclusions: Throughout the four years of surveillance, the Iberian and Brazilian MRSA types and their single subtype 
variants together have been responsible for the overwhelming majority (close to 90%) of all MRSA infections in the 
largest teaching hospital of Portugal. The mechanism of epidemicity of these two multiresistant international MRSA 
clones remains to be elucidated. 
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The average incidence of methicillin-resistant Stuphylo- 
coccus uureus (MRSA) in Portugal was reported to be 
close to 60% during 1992 [1,2]. Typing MRSA strains 
is of critical importance for infection control, and 
molecular techniques have good discriminatory power 
for this purpose [3,4]. The evaluation of MRSA clones 
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Table 1 
de Coimbra, Coimbra, Portud 
Phenotypic and genotypic typing of the 37 MRSA isolates collected in 1992-93 in the Hospitais da Universidade 
Antibiogram 
Resistant to a panel Methicillin Clal- 
ITQB Isolation of nine antibioticsa disk Spcb ClaI-mecA Tn554 PFGE 
Ref. date Service/Ward Source/Product except for: (mm) (500 mg/L) polymorph pattern pattern 
HUCl 11/12/92 
HUC3 9/12/92 
HUC4 15/12/92 
HUC5 15/12/92 
HUC6 15/12/92 
HUC8 15/12/92 
HUC9 16/12/92 
HUClO 16/12/92 
HUCll  15/12/92 
HUC19 17/12/92 
HUC20 17/12/92 
HUC21 18/12/92 
HUC3l 31/12/92 
HUC36 8/1/93 
HUC39 12/1/93 
HUC41 18/1/93 
HUC47 21/1/93 
HUC49 25/1/93 
HUCSI 26/1/93 
HUC57 29/1/93 
HUC59 29/1/93 
HUC73 26/1/93 
HUC74 26/1/93 
HUC14 15/12/92 
HUC30 1/1/93 
HUC71 17/2/93 
HUC25 24/12/92 
HUC32 7/1/93 
HUC40 12/1/93 
HUC64 8/2/93 
HUCIR 19/12/92 
HUC67 15/2/93 
HUC46 19/1/93 
HUC50 26/1/93 
HUC42 19/1/93 
HUC27 23/12/92 
HUC63 - 
Surgery 3 
ICU 
Orthopedics 5 
Psychiatry 
Medicine 1 
Surgery 1 
Orthopedics 2 
Orthopedic? 2 
Orthopedics 2 
Orthopedics 2 
Surgery 
Surgery 1 
Neurotraumatology 
Gastroenterology 
Orthopedics 5 
Nephrology 
Orthopedics 5 
Orthopedics 5 
Orthopedics 5 
Surgery 2 
Endocrinology 
Surgery 3 
Medicine 2 
Orthopedics 5 
Medicine 3 
Surgery 3 
Orthopedics 5 
Heart surgery 
Surgery 3 
Orthopedics 5 
ICU 
Orthopedics 2 
Orthopedics 2 
Orthopedics 5 
Orthopedics 5 
Orthopedics 5 
Heart surgery 
Wound exudate 
Blood culture 
Wound exudate 
Wound exudate 
Wound exudate 
Wound exudate 
Pleural hquid 
Wound exudate 
Wound exudate 
Wound exudate 
Pus 
Catheter 
Wound exudate 
Wound exudate 
Wound exudate 
Urine 
Wound exudate 
Blood culture 
Wound exudate 
Wound exudate 
Urine 
Wound exudate 
Wound exudate 
Wound exudate 
Urine 
Blood culture 
Wound exudate 
Wound exudate 
Peritoneal liquid 
Wound exudate 
Wound exudate 
Wound exudate 
Wound exudate 
Wound exudate 
Wound exudate 
Wound exudate 
Wound exudate 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
SXT 
18 
17 
14 
I4 
18 
17 
15 
17 
14 
14 
16 
14 
14 
13 
12 
13 
13 
18 
17 
10 
22 
13 
15 
18 
18 
13 
19 
14 
11 
15 
21 
12 
15 
14 
13 
17 
13 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
K 
R 
R 
R 
K 
R 
R 
R 
R 
R 
R 
R 
R 
K 
R 
R 
R 
K 
S 
S 
S 
K 
R 
R 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
1 
I 
I 
I 
1 
I 
I 
I 
I 
I 
I 
I 
I 
I 
XI I 
XI1 
XI1 
VIII 
XI 
XI 
XI 
XI 
1 
I 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
I 
CT 
(7 
E 
E 
E 
E 
B 
€3 
B 
B 
E 
E 
A10 
A2 
A1 1 
A10 
A2 
A2 
A1 
A7 
A10 
A1 
A5 
A1 
A2 
A6 
A7 
A2 
A1 
A3 
A4 
A2 
A9 
A10 
A4 
A1 
A1 1 
A1 
A1 
A3 
A1 
A8 
A1 
B5 
B2 
E 
E 
C 
D 
ICU, intensive care unit; SXT, sulfamethoxazole; R, resistant; S, sensitive; I, intermediate. 
'Cefotaxime, ciprofloxacin, erythromycin, gentamicin, imipenem, oxacdlin, penicillin, SXT, vancomycin (all isolates were susceptible to 
vancomycin). 
Spc, spectinomycin 
circulating in a hospital is important for the 
identification of endemic strains and strains responsible 
for outbreaks of MRSA disease. In a global perspective, 
these kinds of data may also answer the ultimate 
question of which microbial factors are involved with 
the success of epidemic strains in causing infection and 
colonization of human hosts. In this study, we have 
performed a survey of MRSA clones present in the 
largest teaching hospital in Portugal-the Hospitais da 
Universidade de Coimbra-using a combination of 
DNA-fingerprinting techniques that has already been 
successfully used for the identification of clones 
involved in several MRSA outbreaks [5-71, and also for 
the tracking of the geographic spread of MRSA clones 
[8-121. 
MATERIALS AND METHODS 
Hospital 
The Hospitais da Universidade de Coimbra (HUC) is 
the largest (1 600-bed) teaching hospital in Portugal, 
and is located in Coimbra, the third largest city in the 
country. This hospital has 30 different services, with 14 
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Table 2 
de Coimbra, Coimbra, Portugal 
Phenotypic and genotypic typing of the 36 MRSA isolates collected in 1994-95 in the Hospitais da Universidade 
Antibiogram 
Resistant to a panel Methicillin ClaI- 
ITQB Isolation of nine antibiotics" disk Spc' ClaI-med Tn554 PFGE 
Ref. date Sewice/Ward Source/Product except for: (mm) (500 mg/L) polymorph pattern pattern 
HUC75 
HUC76 
HUC84 
HUC88 
HUC113 
HUC117 
HUC118 
HUC122 
HUC128 
HUC129 
HUC132 
HUC134 
HUC140 
HUC141 
HUC146 
HUC120 
HUC85 
HUC92 
HUC112 
HUC81 
HUC96 
HUC77 
HUC89 
HUC90 
HUC91 
HUC97 
HUClOO 
HUC108 
HUCllO 
HUCll4  
HUC116 
HUC121 
HUC123 
HUC131 
HUC127 
HUC136 
1/11/94 
23/11/94 
30/11/94 
30/11/94 
4/12/94 
14/12/94 
15/ 12/94 
17/ 12/94 
27/12/94 
27/12/94 
27/12/94 
28/12/94 
2/1/95 
2/1/95 
7/1/95 
15/ 12/94 
30/11/94 
4/12/94 
13/ 12/94 
25/11/94 
6/12/94 
24/11/94 
1/12/94 
3/12/94 
3/12/94 
6/12/94 
9/12/94 
12/12/94 
13/12/94 
14/ 12/94 
14/ 12/94 
16/12/94 
19/12/94 
21 /12/94 
27/12/94 
1/1/95 
ICU 3 
Neurotraumatology 
Orthopedics 5 
Orthopedics 1 M 
Neurotraumatology 
Infectious Diseases 
Orthopedics 5 
Orthopedics 4 
Surgery 3 
Infectious Diseases 
Hematology 
Surgery 3 
Neurology 2 
Surgery 3 
ICU 
Orthopedics 5 
Orthopedics 5 
Orthopedics 1 M 
Infectious Diseases 
Orthopedics 5 
Orthopedics 5 
Surgery 3 
Surgery 3 
Surgery 3 M 
Surgery 2 M 
Endocrinology 
Endocrinology 
Transplant Unit 
Surgery 2 W 
Neurotraurnatology 
Surgery 2 M 
ICU 
ICU 
Surgery 3 M 
Plastic Surgery 
Nephrology 
Wound exudate SXT 
Wound exudate SXT 
Wound exudate SXT 
Wound exudate SXT 
Bronchial aspirate SXT 
Catheter SXT 
Wound exudate 
Wound exudate SXT 
Blood SXT 
Urine SXT 
Urine SXT 
Wound exudate SXT 
Sputum 
Wound exudate SXT 
Catheter SXT 
Wound exudate SXT 
Wound exudate SXT 
Wound exudate ERY, GEN, SXT 
Blood SXT 
Secretion/exudate ERY, GEN, SXT 
Wound pus ERY, GEN, SXT 
Pleural liquid 
Wound exudate 
Exudate 
Catheter 
Exudate 
Exudate 
Secretion/exudate 
Wound exudate 
Sputum 
Secretion/exudate 
Bronchial aspirate 
Bronchial aspirate 
Wound exudate 
Secretiodexudate SXT 
Catheterlexudate CIP, ERY, GEN, IMI, 
SXT 
8 
12 
15 
11 
11 
12 
15 
11 
12 
13 
15 
15 
14 
14 
14 
15 
10 
13 
13 
13 
10 
12 
11 
10 
11 
12 
12 
15 
11 
14 
15 
13 
11 
15 
17 
28 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
S 
R 
S 
S 
S 
I 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
I 
R 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
XI1 
XI1 
XI1 
XI1 
XI1 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XIV 
I1 
E A2 
E A2 
E A 3  
E A 2  
E A13 
E A2 
E A3 
E A1 
E A2 
E A 2  
E A15 
E A 2  
E A3 
E A2 
E A16 
J A14 
E A12 
E A1 
E A 2  
NH A10 
NH A15 
B B2 
B B1 
B B1 
B B1 
B B1 
B E l  
B B1 
B B1 
B B3 
B B1 
B B1 
B B4 
B B1 
DD E 
NH H 
ICU, intensive care unit; SXT, sulfamethoxazole; ERY, erythromycin; GEN, gentamicin; CIF', ciprofloxacin; IMI, imipenem; R, resistant; 
S, sensitive; I, intermediate, NH, no homology; M, men; W, women. 
'Cefotaxime, CIF', ERY, GEN, IMI, oxacillin, penicillin, SXT, vancomycin (all isolates were susceptible to vancomycin). 
'Spc, spectinomycin. 
surgery units and nine intensive care units. In 1992, the 
admission rate was about 47 000 with service provided 
to about 267 000 ambulatory patients. In 1993, those 
figures increased to 49 000 and 291 000, respectively. 
For 1994-96 the numbers were as follows: 1994, 
50 000 and 320 000; 1995, 49 000 and 312 000; 1996, 
50000 and 316000. The percentage of S. aureus 
among Gram-positive isolates was 32% in 1992, 36% 
in 1993, 35% in 1994, 37% in 1995 and 39% in 1996. 
The frequency of MRSA during the same years was 
56%, 53%, S1%, 56% and 60%. 
Clinical isolates 
We have studied 121 single-patient isolates of MRSA 
and eight more isolates recovered from three patients. 
The 129 MRSA isolates were recovered from infection 
sites of patients in different wards, during three 
collection periods: 37 isolates between November 1992 
and February 1993,36 isolates between November 1994 
and January 1995, and 56 isolates during the months of 
October and November 1996 (see Tables 1-3). 
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Table 3 
Coimbra, Coimbra. Portugal 
Phenotypic and genotypic typing of the 56 MRSA isolates collected in 1996 in the Hospitais da Universidade de 
Antihiogram 
Resistant to a panel Methicillin Clal- 
ITQB Isolation of 12 antibiotics” disk Spc’ ClaI-med Tn554 PFGE 
Ref. date Service/Ward Source/Product except for: (mm) (500 mg/L) polymorph pattern pattern 
HUC157 15/11/96 
HUC169 15/11/96 
HUC165 10/11/96 
HUC171 12/11/96 
HUC174 6/11/96 
HUC175 6/11/96 
HUC176 9/11/96 
HUC180 6/11/96 
HUC183 7/11/96 
HUC195 28/10/96 
HUC197 28/10/96 
HUC1.55 25/11/96 
HUC156 23/11/96 
HUC159 15/11/96 
HUC160 18/11/96 
HUC164 19/11/96 
HUC172 15/11/96 
HUC184 9/11/96 
HUC198 25/10/96 
HUC203 24/10/96 
HUC204 25/10/96 
HUC158 18/11/96 
HUC161 19/11/96 
HUC166 7/11/96 
HUC173 9/11/96 
HUC187 29/10/96 
HUC191 28/10/96 
HUC168 12/11/96 
HUC177 11/11/96 
HUC193 25/10/96 
HUC200 23/10/96 
HUC167 11/11/96 
HUC201 22/10/96 
HUC149 23/11/96 
HUC151 25/11/96 
HUC152 20/11/96 
HUC153 20/11/96 
HUC154 22/11/96 
HUC162 16/11/96 
HUC163 19/11/96 
HUC178 9/11/96 
HUC179 7/11/96 
HUC181 9/11/96 
HUC185 9/11/96 
HUC186 5/11/96 
HUC188 4/11/96 
HUC190 29/10/96 
HUC192 28/10/96 
HUC202 18/10/96 
HUC150 18/11/96 
HUC170 14/11/96 
HUC196 24/10/96 
Surgery 3 UCP 
Intensive Medicine 
Gastroenterology M 
Surgery 3 UCP 
Medicine 2 
Medicine 2 
Orthopedics 5 
Burn Unit 
Orthopedics 5 
Orthopedics 5 
Intensive Medicine 
Medicine 1 
Intensive Medicine 
Intensive Medicine 
Surgery 3 UCP 
Surgery 3 M 
Surgery 3 UCP 
Vascular Surgery 
Neurotraumatology 
Nephrology 
Intensive Medicine 
Surgery 3 M 
Orthotraumatology 
Nephrology 
Neurosurgery 
Nephrology 
Nephrology 
Neurotraumatology 
Intensive Medicine 
Nephrology 
Intensive Medicine 
Intensive Medicine 
Intensive Medicine 
Transplant Unit 
Orthopedics 1 
Infectious Diseases 
Transplant Unit 
Medicine 3 W 
Transplant Unit 
Neurosurgery 
Surgery 2 W 
Infectious Diseases 
Transplant Unit 
Transplant Unit 
Surgery 2 W 
Surgery I M 
Transplant Unit 
Transplant Unit 
Neurotraumatology 
Transplant Unit 
Transplant Unit 
Neurotraumatology 
Wound exudate FOS, SXT, PRI 
Bronchial aspirate FOS, SXT 
Blood FOS, SXT 
Catheter FOS, SXT, PRI 
Blood FOS, TET, SXT, PRI 
Blood FOS, SXT, PRI 
Urine FOS, SXT, PRI 
Catheter FOS, SXT 
Wound exudate SXT, PRI 
Wound exudate FOS, SXT 
Wound exudate FOS, SXT, PRI 
Pus FOS, SXT 
Bronchial aspirate FOS, SXT 
Bronchial aspirate FOS, SXT 
Pleural hquid FOS, SXT, PRI 
Wound exudate FOS, SXT 
Wound exudate FOS, SXT, PRI 
Wound exudate FOS, RFA, SXT 
Urine/vesical probe FOS, SXT, PRI 
Bronchial aspirate RFA, PRI 
Bronchial aspirate FOS, SXT 
Catheter FOS, SXT 
Wound exudate FOS, SXT 
Blood ERY, FOS, SXT, PRI 
Bronchial aspirate ERY, FOS, RFA, SXT 
PRI 
Blood ERY, FOS, SXT, PRI 
Blood ERY, FOS, TET, SXT, 
PRI 
Bronchial aspirate ERY, FOS, RFA, SXT 
PRI 
Bronchial aspirate FOS, SXT, PRI 
Blood FOS, RFA, SXT, PRI 
Blood FOS, RFA, SXT, PRI 
Bronchial aspirate ERY, FOS, RFA, SXT 
PRI 
Pleural liquid FOS, RFA, SXT, PRI 
Bronchial aspirate RFA, PRI 
Wound exudate NIT, PRI 
Blood RFA, PRI 
Catheter RFA, PRI 
Sputum RFA 
Pleural liquid RFA, PRI 
Bronchial aspirate RFA, PRI 
Catheter RFA, PRI 
Blood RFA, PRI 
Feces RFA, PRI 
Sputum RFA, PRI 
Blood RFA, PRI 
Wound exudate RFA, PRI 
Bronchal aspirate RFA, PRI 
Bronchial aspirate RFA, PRI 
Bronchal aspirate RFA, PRI 
Catheter SXT, PRI 
Catheter RFA, PRI 
Urine RFA, PRI 
13 
12 
9 
12 
12 
15 
13 
12 
13 
12 
12 
14 
15 
12 
12 
13 
12 
11 
12 
14 
13 
12 
11 
11 
17 
15 
11 
11 
14 
12 
14 
11 
14 
22 
16 
17 
15 
15 
10 
10 
13 
12 
10 
11 
12 
14 
13 
12 
11 
16 
11 
11 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
R 
S 
R 
R 
R 
R 
R 
R 
R 
S 
R 
R 
R 
S 
K 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
R 
R 
S 
S 
S 
S 
S 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I1 
I1 
I1 
I1 
XI1 
XI I 
XI1 
XI1 
XI1 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
XI 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
E 
J 
J 
J 
J 
J 
J 
J 
J 
J 
J 
NH 
NH 
E 
E 
E 
E 
E 
E 
E 
E 
N H  
J 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
B 
N H  
NH 
N H  
n 
AS 
A2 
A8 
A1 8 
A2 
A2 
A19 
A19 
A20 
A2 
A2 
A17 
A2 
A2 
A18 
A6 
A18 
A1 
A2 
B6 
A2 
A18 
A2 
A1 
A10 
A1 
A1 
A10 
A10 
A1 
A1 
A10 
A1 
B2 
B5 
B6 
B1 
B7 
B6 
B2 
B6 
B6 
B1 
B1 
B6 
B6 
B6 
B6 
B2 
B1 
B1 
B2 
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Table 3 Continued. 
Antibiograrn 
Resistant to a panel Methican CfaI- 
ITQB Isolation of 12 antibiotics" Ask Spcb ClaI-mecA Tn554 PFGE 
Ref. date Service/Ward Source/Product except for: (mm) (500 mg/L) polymorph pattern pattern 
HUC199 20/10/96 Intensive Medicine Bronchal aspirate RFA, PRI 11 S XI NH B8 
a G  
NH G 
HUC182 7/11/96 Vascular Surgery Wound exudate RFA, PRI 14 S XI B F 
HUC189 4/11/96 Surgery I M PdAbscess FOS, OFL, RFA 16 R I1 
FOS, OFL, RFA, SXT 18 S XI HUC194 - - - 
~ ~~~ ~~~~~~~ 
ICU, intensive care unit; FOS, fosfomycin; SXT, sulfamethoxazole; PRI, pristinamycin; TET, tetracycline; RFA, rifampin; 
ERY, erythromycin; NIT, nitrofurantoin; OFL, ofloxacin; R, resistant; S, sensitive; I, intermediate, NH, no homology; M, men; W, women. 
TRY, FOS, fusidic acid, gentamicin, NIT, OFL, oxacillin, RFA, TET, SXT, PRI, vancomycin (all isolates were susceptible to NIT and 
vancornycin). 
bSpc, spectinomycin. 
Reference strains 
Representative isolates of 'Iberian' and 'Brazilian' 
MRSA clones were included in this study: PER34 [6], 
HPV107 [8], HDG3 [7] and HU24 [lo]. 
Assay for coagulase production 
The classification of the isolates as S.  aureus was based 
on coagulase production (Bacto Coagulase Plasma, 
Difco, Detroit, USA). 
Evaluation of methicillin resistance 
A rapid preliminary screening of the methicihn 
resistance level was carried out by plating cultures on 
trypticase soy agar (TSA) plates and measuring the 
diameter of inhibition halos around a disk containing 
1 mg of methicillin, after 24 h of incubation at 37OC 
[13]. The cultures were also plated on TSA plates 
containing methicillin concentrations of 2, 5, 10 and 
25 mg/L [14]. Five strains were used as controls: 
RN2677 (susceptible), CDCl (heterogeneous resist- 
ance class l), NYBH3 (heterogeneous resistance class 
2), BM79 (heterogeneous resistance class 3) and COL 
(homogeneous resistance class 4) [14]. 
Antimicrobial susceptibility testing 
All isolates were tested by the Vitek automatic system 
(Vitek Systems, Hazelwood, Mo., USA) and sporadic 
isolates were also tested by disk difision methods [15], 
when results needed to be confirmed. The panel of 
antibiotics tested from 1992 to 1995 was: cefotaxime, 
ciprofloxacin, erythromycin, gentamicin, imipenem, 
oxacillin, penicillin, sulfmethoxazole (SXT) and vanco- 
mycin. In 1996 the panel was changed to erythro- 
mycin, fosfomycin, fusidic acid, gentamicin, nitro- 
furantoin, ofloxacin, oxacillin, rifampin, tetracycline, 
SXT, pristinamycin and vancomycin. Resistance to 
spectinomycin and erythromycin was also evaluated in 
the research laboratory by inoculating late-log-phase 
cultures onto TSA plates containing, respectively, 
500 mg/L [16] and 10 mg/L of the antibiotics. 
Preparation of chromosomal DNAs for conventional and 
pulsed-field gel electrophoresis 
This was carried out by the method originally 
described by Goering and Winters [17] and extensively 
modified by de Lencastre et al [5]. 
Restriction digestions 
Restriction digestions of chromosomal DNA with 
SmaI and Bspl06 (a ClaI isoschizomer) and of plasmidic 
DNA with XbaI, PstI and EcoRV were performed 
according to the manufacturer's recommendations 
(Stratagene, La Jolla, CA, USA). 
Conventional electrophoresis 
Gels were run with 0.8% agarose in X l  TAE buffer 
(40 mM Tris, 1 mM EDTA, glacial acetic acid 0.11% 
v/v, pH 8.0) [18] for 16 h at 30 mV. 
Pulsed-field gel electrophoresis 
PFGE was carried out using either an LKB-Pharmacia 
2015 Gene Navigator apparatus Pulsaphor system 
(Pharmacia-LKB, Stockholm, Sweden) or a CHEF- 
DR I1 apparatus (Bio-Rad, USA). The conditions used 
for the Pulsaphor system were the following, as already 
described [9]: 22 h run time in X0.5 TBE buffer 
(50 mM Tris, 50 mM boric acid, 1 mM EDTA, pH 
8.0) at 10°C and 210 V with pulses of 5 s for 5 h, 10 s 
for 6 h, 30 s for 6 h and 60 s for 5 h. When the CHEF 
apparatus was used, the gels were run for 23 h at 2 4 O C  
in X0.5 TBE buffer, at 6 V/cm with an initial forward 
time of 1 s and a final forward time of 30 s [ S ] .  
Southern blotting and DNA hybridization 
DNA transfer to Hybond Nf membranes (Amersham 
International, Little Chalfont, UK) was performed 
either by standard methodology [18], or with a vacuum 
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blotting apparatus (Vaccu-blot, Pharmacia, Sweden), 
according to the manufacturer’s instructions for con- 
ventional gels and following the previously described 
protocol for PFGEs [5]. The DNA probes used were a 
1.96-kb PstI-XbaI internal fragment of the mecA gene 
cloned in pTZ19 [19] and a 5.534-kb EcaRV fragment 
of the Tn554 transposon cloned in a pBlueScript I1 
vector [16]. Probes were labeled using the Megaprime 
Radioactive Labeling System, RPN1606, or the ECL 
Random Prime Labeling System Version 11, RPN3040 
(Amersham International, UK) and the (pre)hybridiz- 
ation was performed according to the manufacturer’s 
instructions. 
RESULTS 
Phenotypic analysis 
All but three of the isolates received showed coagulase 
production and a high level of resistance to methicillin: 
halos smaller than 20 mm when tested with 1-mg 
methicillin disks [I31 and no growth inhibition on TSA 
plates with methicihn concentrations up to 25 mg/L 
XI vm XII - I 
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Figure 1 
probe. This picture shows the predominant Cla1::mecA 
polymorphs-polymorph I (strains HUC1, HUC51, 
HUC14, HUC71) and polymorph XI (strains HUC18 and 
HUC67)-found in the 129 MRSA isolates typed, the 
single represented polymorph VIII (strain HUC64) and the 
new polymorph XI1 (strains HUC25, HUC32 and 
HUC40). The new polymorph XI1 is very similar to the 
previously described polymorph I, differing only in a 
slightly heavier, larger band. The names of the Cla1::mecA 
polymorphs are displayed on the top of the picture. The 
molecular sizes (kb) of the Cla1::merA bands are indicated. 
Hybridization of ClaI dlgests with the m e d  
[14,20]. One methicillin-resistant isolate was found to 
be coagulase negative and, therefore, was not included 
in this study. Two isolates, classified as MRSA in the 
first tests performed by the hospital clinical micro- 
biology laboratory, turned out to be MSSA-halos of 
32 and 42 mm and no hybridization with the specific 
mecA probe. Since these isolates had MICs of 5 mg/L, 
they may possess alternative mechanisms of resistance 
to methicillin [14,21]. Eventually, 129 MRSA isolates 
were selected for characterization. 
Molecular typing 
ClaI digests of chromosomal DNAs were separated 
by conventional gel electrophoresis, transferred to 
membranes and hybridized, first with the mecA probe 
(to identify the mecA polymorphs) and then with the 
Tn554 probe (to identify Tn554 types). Chromosomal 
DNAs mgested with SmaI were separated by PFGE, to 
produce different DNA band patterns, which were 
compared to one another and were classified into 
PFGE types (capital letter) and/or subtypes (capital 
letter with number code) if the PFGE patterns differed 
by only up to three bands [22,23]. These three typing 
methods allowed us to define 22 clonal types among 
the 129 MRSA isolates which differed in mecA 
polymorphisms, ClaI::Tn554 insertion patterns and 
PFGE patterns, as shown in Tables 1-3. Illustrations of 
these typing methods are shown in Figures 1-3. 
Isolates collected in 1992-93 
The 37 isolates included in t h s  set were divided into 
four different Cla1::mecA polymorphs (I, VIII, XI and 
XII) and four different ClaI::Tn554 insertion patterns 
(E, J, B and G ) ,  using letter and number assignments 
defined as in previous communications [6,16]. The 
Cla1::mecA polymorph XI1 and ClaI::Tn554 pattern 0 
have not been described before. The new polymorph 
XI1 is very simdar to the previously described poly- 
morph I, differing only in a slightly heavier big band. 
The isolates could be grouped into five different PFGE 
types (A-E) with 11 subtypes for pattern A (Al-All) 
and two subtypes for pattern B (B2 and B5). When 
these data were combined, nine different clonal types 
could be identified among the 37 MRSA isolates (see 
Tables 1 and 4). The clonal type 1::E::A (‘Iberian 
MRSA’ clone [8]) was represented by 65% of the 
isolates (24 of 37), and 84% of the isolates (31 of 37) 
had the same genomic background, defined as PFGE 
pattern A. The remaining six MRSA isolates included 
two isolates with the clonal type XI::B::B, which, 
after careful comparison [24], was shown to be 
indistinguishable from the ‘Brazilian clone’ of MRSA, 
originally assigned to the Cla1::mecA polyrnorph 111 
[lo]. C1aI::mecA polyrnorph I11 generates two mecA 
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insertion patterns (E, J and B) and the new pattern (5, found in the 129 MRSA isolates studied. CIaI::Tn554 pattern E is 
represented by strains HUC1, HUC51, HUC64, HUC25, HUC32 and HUC40; CIaI::Tn554 pattern J by strain HUC14; 
CIaI::Tn554 pattern B by strains HUC18 and HUC67; and CIaI::Tn554 pattern u by strain HUC71. The names of the 
CIaI::Tn554 insertion patterns are &splayed on the top of the picture. MW is the molecular size marker (1-kb Ladder, 
Gifco, BRL): the molecular sizes (kb) of the ladder bands are indicated. 
Hybridization of ClaI digests with the Tn554 probe. This picture shows the most common ClaI::Tn554 
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Figure 3 
pattern A and B, the two predominant genomic backgrounds, are shown. The minor genomic backgrounds are also 
&splayed. The PFGE pattern names are displayed on the top of the picture: pattern Al, strain HUClY; pattern A2, strain 
HUC31; pattern A3, strain HUC25; pattern A4, strain HUC51; pattern A7, strain HUC39; pattern A16, strain HUC146; 
pattern A18, strain HUC160; pattern A19, strain HUC180; pattern B1, strain HUC89; pattern B2, strain HUC149; pattern 
B3, strain HUC114; pattern B4, strain HUC123; pattern B5, strain HUC151; pattern B6, strain HUC152; pattern C, strain 
HUC42; pattern D, strain HUC27; pattern E, strains HUC46 and HUC50; pattern F, strain HUC182; pattern G, strains 
HUC189 and HUClY4; and pattern H, strain HUC136. MW is the h DNA ladder (New England, Biolabs) and STD is the 
reference strain NCTC8325. The molecular sizes (kb) of the ladder bands are indlcated. 
PFGE major paterns and most important subtypes of SmaI digests. The most important subtypes of PFGE 
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hybridization bands of 2.2 and 4.3 kb, whereas in 
pattern XI the bands are 2.2 and 4.4 kb. 
Isolates collected in 1994-95 
These 36 MRSA isolates were resolved into Cla1::mecA 
patterns I, 11, XI, XI1 and XIV and CIaI::Tn554 
insertion patterns E, J and DD. Cla1::mecA pattern XIV 
has only been seen before in one Portuguese hospital 
[25]. The 36 MRSA isolates could be divided into four 
PFGE patterns: pattern A (with five new subtypes 
A12-A16), pattern B (with three new subtypes B1, B3 
and B4) and single isolates showing PFGE patterns E 
and H. The ‘Iberian MRSA’ (clonal type 1::E::A) was 
represented by 42% of the isolates (15 of 36) and 58% 
of isolates had clonal types related to PFGE pattern A 
(21 of 36). The representation of ‘Brazilian MRSA 
(clonal type X1::B::B) increased to 36% (13 of 36 
isolates). The remaining two clonal types corresponded 
to two isolates (see Tables 2 and 4). 
Isolates collected in 1996 
Among the 56 isolates recovered in 1996, we found 
four Cla1::mecA polymorphs-I, 11, XI and XII-and 
four CIaI::Tn554 patterns-E, B, J and a. The 
CIaI::Tn554 insertion pattern a was first described in 
a Portuguese hospital [5]. The isolates were divided 
into four PFGE patterns: pattern A (with four new 
subtypes A17-A20), pattern B (with three new sub- 
types B6-B8) and two minor patterns (F and G). In this 
set of strains, the clone 1::E::A (‘Iberian MRSA’) 
was still represented by 20% of the isolates (10 of 56), 
and its related clone 1::J::A (differing only in Tn554 
insertion pattern) was also present in an additional 16% 
of the isolates. The PFGE pattern A related clones were 
represented by 57% of the isolates (32 of 56). Clonal 
type X1::B::B (‘Brazilian MRSA’) was found in 29% of 
the isolates (16 of 56) and, together with its closely 
related clone X1::NH::B (loss of Tn554 in four 
isolates), the clone accounted for 36% of the MRSA 
strains (see Tables 3 and 4). 
Antibiotic resistance 
In 1992-93 and 1994-95, the great majority (69 of 73, 
95%) of the MRSA isolates were resistant to all anti- 
biotics included in the panel used by the hospital 
microbiology laboratory, except for vancomycin and 
SXT. O f  the 19 isolates resistant to SXT, 17 belonged 
to clonal type X1::B::B and only one to clone 1::E::A. 
In 1996, the hospital microbiology laboratory began to 
use a new panel of antibiotics (see Table 3). The 1996 
Table 4 
between 1992 and 1996, in the Hospitais da Universidade de Coimbra, Coimbra, Portugal 
Clonal types of 129 MRSA isolates collected during the 4-year surveillance study, 
1992-93 1994-95 1996 
Clonal type 
ClaI::mer&Tn554PFGE n of37 % n of36 % n of56 % 
PFGE pattern A, 
related clonal types 
1::E::A 
1:j::A 
1::o::A 
1::NH::A 
1I::E::A 
XI1::E::A 
XI1::NH::A 
VI1I::E::A 
X1::J::A 
PFGE pattern B, 
related clonal types 
X1::B::B 
X1::NH::B 
1::J::B 
Minor clonal types 
X1::B::E 
X1V:DD::E 
X1::B::F 
1I::a::G 
X1::NH::G 
I1::NH::H 
1::E::C 
1::E::D 
24 
1 
2 
3 
2 
1 
2 
2 
1 
1 
65 15 
2.7 1 
5.4 
8 3 
5.6 1 
2.7 
5.4 13 
5.4 
1 
1 
2.7 
2.7 
42 11 20 
2.8 9 16 
2 3.6 
4 7 
8 4 7 
1.8 
1 1.8 
36 16 29 
4 7 
1 1.8 
2.8 
1 1.8 
1 1.8 
1 1.8 
2.8 
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Figure 4 Evolution of '. 
de Coimbra, Coimbra, Portugal. 
MRSA isolates were also multi-resistant, although they 
remained susceptible to fusidic acid and to nitro- 
furantoin (drugs added to the new panel) and also to 
vancomycin. Resistance to fosfomycin paralleled SXT 
resistance, which was mostly associated with Cla1::mecA 
pattern XI (20 of the 22 SXT-resistant MRSA strains 
carried the mecA polymorph XI). O n  the other hand, 
the majority of rifampin-resistant isolates (25 of 27; or 
93%) did not carry the Cla1::mecA pattern XI, but 
rather the m e d  polymorphs I, I1 and XII. Interestingly 
and unexpectedly, the overwhelming majority (94%) of 
the isolates belonging to clonal type X1::B::B were 
phenotypically susceptible to spectinomycin, in spite 
of the fact that they carried three copies of Tn554 
[16]. The mechanism of this phenomenon is under 
investigation. 
DISCUSSION 
The main purpose of this study was to create an 
inventory of the MRSA clones responsible for MRSA 
infections in the Hospitais da Universidade de 
Coimbra, the largest teaching hospital in Portugal, 
during three brief (2-4 months) surveillance periods 
between 1992 and 1996. We have studied 121 single- 
patient isolates of MRSA and eight multi-isolates 
recovered from three patients. The 129 MRSA isolates 
were recovered from infection sites of patients in 
different wards. The typing methods used in this study 
have different resolving powers and each can provide 
unique molecular information about an MRSA isolate. 
The Cla1::mecA DNA probe tests the variabihty in the 
mecA vicinity, especially between ClaI cutting sites 
da Universidade 
within the gene and its downstream region. The 
ClaI::Tn554 insertion patterns and the location of 
Tn5.54 in SmaI fragments [7,9] provide information 
about the number of copies and chromosomal location 
of this transposon. Finally, PFGE provides an overall 
view of the staphylococcal chromosome through the 
macrorestriction pattern that reflects the distribution of 
SmaI cutting sites. The combination of these three 
methods allows one to define clonal types of MRSA. 
For instance, in relation to PFGE pattern A, we have 
defined nine related clones, which have similar PFGE 
patterns, differing maximally in three bands (which is 
the largest difference a single genetic event can cause) 
[3,22,23]. Taking clone 1::E::A as reference, our 
methods were able to recognize variability in the mecA 
vicinity (clones U::E::A, m::E::A, D : : E : : A  and 
XJ::J::A), loss of transposon Tn554 (clones 1 : :m: :A 
and X1I::M::A) or increase in the Tn.554 copy 
number (I:J:A, 1::o::A and X1::J::A). As the PFGE 
pattern did-not change, these genetic events imply no 
major chromosomal rearrangements and, therefore, 
one may consider these isolates as still being clonally 
related to one another. A different type of situation was 
apparent in some of the minor clones which carried the 
same Cla1::mecA polymorphs in different genomic 
(PFGE) backgrounds, suggesting horizontal transfer of 
the mecA [26,27]. 
Figure 4 illustrates the temporal shifts in MRSA 
clonal types observed in the study. In 1992-93, the first 
period of surveillance, clone 1::E::A was found to 
be dominant in Hospitais da Universidade de Coimbra, 
being represented by 65% of the isolates or, together 
with its related clones, by 84% of all MRSA strains. By 
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1993, this clone, named the ‘Iberian Clone’ [8,24], 
was also dominant in other Portuguese hospitals 
[7,9,24,25,28,29] and its geographic spread had already 
been traced to MRSA outbreaks in Spain [6]. Recently 
this clone has also been found in other European 
countries [30] and in the USA [31]. 
In the second surveillance period, 1994-95, clone 
1::E::A was still dominant, being represented by 42% of 
the isolates or, together with its related clones, by 58%. 
Moreover, the clone XI::B::B spread in the hospital, 
representing 36% of all MRSA isolates from this period, 
whereas in the first period it was only represented by 
two isolates (5%). This clone is identical to the one 
described in Brazil, where it was able to spread in 
hospitals located thousands of kilometers apart [lo]. 
More recently, this clone has also been found in other 
Portuguese hospitals [32,33]. 
In 1996, the last period of this survey, there was a 
drastic decline in the prevalence of clone I::E::A, which 
was only represented by 20% of the isolates. However, 
together with its related clones, it still accounted for 
57% of MRSA isolates. Clone X1::B::B accounted for 
29% (or, together with its related clones, for 38%) of all 
MRSA isolates recovered during the 1996 survey. 
Antibiogram typing has sometimes been described 
as not having enough discriminatory power to distin- 
guish MRSA clones, since they are usually multi- 
resistant to most of the antibiotics used [9]. However, 
in this study, we have found that antibiogram typing 
was able to discriminate the two main clones. There 
was a correlation between SXT resistance and clonal 
type X1::B::B (or X1::NH::B). In 1996, the antibiotic 
panel was changed and an even higher degree of 
discrimination was achieved: co-resistance to SXT and 
fosfomycin for X1::B::B and related clones and resist- 
ance to rifampin for 1::E::A and related clones. Interest- 
ingly according to the clinical laboratory collaborators 
the use of SXT has been decreasing in this hospital. 
This antibiotic was largely used in the treatment of 
urinary infections but since 1994 it has been used 
less. Therefore, the observed shifts in the clonal type 
incidence cannot be explained by an increased usage of 
SXT. 
In 1996, eight multiple isolates were recovered 
from three patients, always from different body sites and 
over a time period of 3-4 days. In one patient, the two 
isolates recovered were exactly the same (XI::B::B4), 
suggesting multisite and stable colonization. tn the 
other two patients the multiple isolates were different: 
XI::NH::B8, X1::E::Al and XI A1 for one patient, 
and XI::NH::BI, X1::B::Bl and XI::B::B6 for the 
other patient. These findings are compatible with 
multiple-cross infections or with in vivo chromosomal 
rearrangements, including acquisition/loss of trans- 
poson Tn5.54. These kind of data are of interest because 
they may eventually provide insights into the niech- 
anism of infection/colonization events. 
While the average rate of MRSA infections has 
remained virtually unchanged in the Hospitais da 
Universidade de Coimbra between 1992 and 1996, the 
application of molecular fingerprinting methods has 
allowed the detection of major shifts in the nature of 
MRSA strains inhabiting the hospital during this 
period the decline in the representation of the ‘Iberian 
clone’ (from 65% in 1992-93 to 20% in 1996) and the 
parallel rise in the incidence of a second distinct MRSA 
lineage (from 5% in 1992-93 to 29% in 1996), which 
was indistinguishable from the MRSA clone widely 
spread in Brazilian hospitals [lo]. At the time of the last 
collection period in 1996, these two multiresistant 
clones were cohabiting in the hospital, with the 
‘Brazilian clone’ present in relative abundance. How- 
ever, a closer look at the different DNA fingerprints 
allows one to identify several other processes as well. 
One of these is the apparent acquisition of a second 
copy of Tn554 of the ‘Iberian clone’, leading to the 
emergence of the lineage I:d::A, which becomes a 
significant clonal type (representing 16% of all MRSA 
isolates) in the 1996 sample. Together with the original 
1::E::A (20%), plus a variant 1::NH::A (in which Tn5.54 
was lost) (3.6%), these three versions of the ‘Iberian 
clone’ make up 39.6% of the 1996 sample. Yet another 
process is the proliferation of PFGE subtypes: as many 
as 21 (Al-A21) in the case of PFGE type A, and seven 
(Bl-B7) of PFGE type B. If one assumes that molecular 
events form the basis of subtype variation (e.g. acqui- 
sition and/or loss of transposable elements, prophages, 
etc.) occurring in the original ‘Iberian’ and ‘Brazilian’ 
clones during their ‘recycling’ in the Coimbra hospital, 
then the greater frequency of the PFGE A subtype 
variants over that of PFGE type B would parallel the 
earlier ‘arrival’ and larger population size of the Iberian 
‘clone’. 
The single most striking feature of the observations 
described here is the virtually complete dominance of 
MRSA infections in this Portuguese hospital by two 
multiresistant international clones-at least one of 
which may have been imported to Portugal from South 
America. In 1994-95, 94% of MRSA infections were 
caused by the combined contributions of the ‘Iberian’ 
(58%) and the newly arrived ‘Brazilian’ (36%) clones 
and, in 1996, these figures were 57% (‘Iberian-like 
clones’) and 38% (‘Brazilian-like clones’). These find- 
ings suggest that both the ‘Iberian’ and ‘Brazilian’ 
clones must have substantial reservoirs in Portuguese 
hospitals. In fact, these two MRSA clones apparently 
do not colonize healthy populations, according to a 
survey for MRSA carriage performed in children 
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attending day-care centers, draftees and high school and 
university students [34]. The microbiological factors 
that may contribute to the remarkable epidemicity of 
these MRSA clones are currently under investigation. 
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